Publications by Professor Pierre Bedossa - ePrints

Browsing publications by Professor Pierre Bedossa.

Newcastle Authors	Title	Year
Professor Arun Sanyal Professor Pierre Bedossa Professor Quentin Anstee	A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis	2024
Professor Pierre Bedossa Professor Quentin Anstee	A Randomized Controlled Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis	2024
Professor Fiona Oakley Dr Simon Cockell Dr Olivier Govaere Professor Ann Daly Professor Arun Sanyal et al.	An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)	2024
Professor Quentin Anstee Professor Pierre Bedossa	Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study	2024
Professor Quentin Anstee Professor Pierre Bedossa	Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis	2024
Kristy Wonders Dr Dina Tiniakos Professor Pierre Bedossa Professor Quentin Anstee	Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study	2023
Kristy Wonders Dr Dina Tiniakos Professor Pierre Bedossa Professor Cliff Brass Professor Quentin Anstee et al.	Machine learning algorithm improves detection of NASH (NAS-based) and at-risk NASH: a development and validation study	2023
Dr Katherine Johnson Dr Peter Leary Dr Olivier Govaere Dr Matthew Barter Sarah Charlton et al.	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance	2022
Professor Alastair Burt Professor Pierre Bedossa Dr Dina Tiniakos	Fifty years of impact on liver pathology: a history of the Gnomes	2021
Dr Olivier Govaere Dr Dina Tiniakos Professor Pierre Bedossa Dr Simon Cockell Dr Massimo Younes et al.	NASH limits anti-tumor surveillance in immunotherapy-treated HCC	2021
Professor Pierre Bedossa Professor Quentin Anstee Professor Arun Sanyal	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study	2020
Professor Pierre Bedossa	Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease	2020
Professor Quentin Anstee Professor Pierre Bedossa	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study	2020
Professor Quentin Anstee Dr Rebecca Darlay Dr Simon Cockell Dr Olivier Govaere Dr Dina Tiniakos et al.	Genome-Wide Association Study of Non-Alcoholic Fatty Liver and Steatohepatitis in a Histologically-Characterised Cohort	2020
Dr Timothy Hardy Kristy Wonders Dr Massimo Younes Professor Pierre Bedossa Entesar Betelmal et al.	The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease	2020
Dr Olivier Govaere Dr Simon Cockell Dr Dina Tiniakos Dr Rachel Queen Dr Massimo Younes et al.	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis	2020
Professor Quentin Anstee Professor Pierre Bedossa	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease	2019
Professor Quentin Anstee Professor Pierre Bedossa Professor Arun Sanyal	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial	2019
Dr Marie Boyle Dr Dina Tiniakos Dr Olivier Govaere Dr Massimo Younes Professor Stuart McPherson et al.	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease	2019
Professor Arun Sanyal Professor Quentin Anstee Professor Pierre Bedossa	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis	2019
Professor Alastair Burt Professor Pierre Bedossa Professor Helen Reeves	Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)	2018
Professor Chris Day Professor Pierre Bedossa	Substantial variability of the diagnostic accuracy of serum fibrosis markers across multiple cohorts of nash patients in various centers : the case for the negative predictive value	2015
Professor Pierre Bedossa Professor Alastair Burt Dr Dina Tiniakos Dr John Brain Dr Yvonne Bury et al.	Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease	2014
Professor Pierre Bedossa Professor Alastair Burt Dr Dina Tiniakos	Well differentiated hepatocellular neoplasm of uncertain malignant potential: Proposal for a new diagnostic category	2014